We won! 2026 Best Overall Patient Engagement Platform →

Life Sciences · Psychedelics

Observation infrastructure for psychedelic trials.

Compressed dosing windows, functional unblinding, therapist fidelity, novel endpoint categories: the design challenges psychedelic programs face are exactly the ones traditional PRO tooling was never built to solve. Videra was purpose-built for the observation gaps psychedelic trials expose.

Four places psychedelic trials break the standard endpoint stack.

Gap 1 · Within-Session Signal

The therapeutic signal lives inside the session.

Peak effects can arrive and resolve faster than a paper PRO can be administered. Affect trajectory, somatic response, and vocal shifts move on a timescale traditional scales weren't built for. Continuous multimodal observation captures what PROs miss.

A paper PRO samples one moment. Wherever it lands, everything on either side is missed

Gap 2 · The Regulatory Bar

Objective evidence is a design problem, not a hope.

Regulators and reviewers are increasingly asking for functional unblinding evidence, therapist fidelity records, and objective behavioral endpoints. These have to be designed in from Phase 2 forward, not retrofitted after the fact.

Functional unblinding evidence

Objective behavioral record, session by session

Therapist fidelity records

Auditable video and adherence logs

Objective behavioral endpoints

Designed in from Phase 2 forward

The dossier reviewers ask for, built during the trial, not reconstructed after it

Gap 3 · Therapist Consistency at Scale

Facilitator variability is the largest hidden risk.

FidelityView creates the observable, auditable record of dosing sessions. QAview verifies protocol adherence across every site and every session, converting facilitator variability from an unknown into a measurable factor.

Site A ✓ Site B ✓ Site C ✓ Site D ✓ Every site, every session

Gap 4 · Between-Session Durability

The therapeutic effect is measured between visits.

Therapeutic durability happens off-site, in the weeks and months after dosing. RemoteView captures the symptom trajectories PROs can't touch, across the range of indications psychedelic programs address.

Dashed verticals: RemoteView check-ins · every symptom trajectory, on the patient's own device

Three trial design patterns we build for.

Design pattern 01

Compressed-window sessions

Trials where the entire psychoactive window is shorter than a single PRO administration. Continuous behavioral capture is the only viable endpoint. Multimodal signal timestamps onset, peak, and resolution in real time.

Design pattern 02

Therapist-assisted protocols

Programs where facilitator involvement is core to the therapeutic model, and consistency across sites drives outcomes. FidelityView plus Assess delivers the audit layer that regulators and monitors expect.

Design pattern 03

Novel endpoint categories

Trials where therapeutic effect needs to be measured objectively, beyond self-report and independent of subjective experience. Behavioral biomarkers isolate the signal that matters from confounding factors.

Built for regulated work.

Videra runs in clinical trials, hospital systems, and pharma-sponsored programs. Compliance and audit trails are foundational.

HIPAA SOC 2 Type II 21 CFR Part 11 FDA SaMD E2E Encrypted

Let's keep talking

A 30-minute conversation, tailored to your program.

Bring us a question and we'll walk you through what behavioral evidence looks like inside your specific trial or commercial program.